Literature DB >> 23578036

Rectal cancer recurrence: factors and mechanisms.

.   

Abstract

OBJECTIVE: There have been significant developments in treatment for rectal carcinoma, both in surgical and adjuvant therapy. They may however have associated morbidity and hence individualized therapy for rectal cancer is desirable, to optimize treatment but avoid over-treatment for cases where the risk of recurrence is low.
MATERIALS AND METHODS: A literature review was undertaken of the reported incidence of recurrence of rectal carcinoma following curative surgery, factors which predispose to recurrence and proposed mechanisms for recurrence, and the evidence for each critically evaluated.
RESULTS: The incidence of local recurrence of rectal carcinoma following curative resection ranges from 2.6% to 32%, with an average of 15%. Tumour stage is the strongest predictor of tumour recurrence. Upstaging using molecular biology may predict increased risk of recurrence but is not yet proven. Histological factors including differentiation and vascular invasion increase recurrence but are imprecise. Tumour microvascular density and vascular endothelial growth factor (VEGF) levels may be predictive but need refinement. Adequate resection margins are important but recurrence may occur despite this. Tumour cell spillage and distant dissemination may be a mechanism for tumour recurrence following curative resection, but further research is required before this could be applied clinically.
CONCLUSION: Recurrence of rectal cancer remains a significant problem following 'curative' surgery. Multiple factors may influence recurrence risk, though currently however only tumour stage and histological resection margins have demonstrated sufficient importance for management decisions to be made upon them.

Entities:  

Year:  2000        PMID: 23578036     DOI: 10.1046/j.1463-1318.2000.00148.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  8 in total

1.  Cost of care for colorectal cancer in Ireland: a health care payer perspective.

Authors:  L Tilson; L Sharp; C Usher; C Walsh; Whyte S; A O'Ceilleachair; C Stuart; B Mehigan; M John Kennedy; P Tappenden; J Chilcott; A Staines; H Comber; M Barry
Journal:  Eur J Health Econ       Date:  2011-06-03

2.  Outcome and prognostic factors of local recurrent rectal cancer: a pooled analysis of 150 patients.

Authors:  F Selvaggi; C Fucini; G Pellino; G Sciaudone; I Maretto; I Mondi; N Bartolini; F Caminati; S Pucciarelli
Journal:  Tech Coloproctol       Date:  2014-11-11       Impact factor: 3.781

3.  Extended lateral pelvic sidewall excision (ELSiE): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall.

Authors:  I Shaikh; W Aston; G Hellawell; D Ross; S Littler; D Burling; M Marshall; J M A Northover; A Antoniou; J T Jenkins
Journal:  Tech Coloproctol       Date:  2014-11-08       Impact factor: 3.781

Review 4.  Modern management of rectal cancer: a 2006 update.

Authors:  Glen-C Balch; Alex De Meo; Jose-G Guillem
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

Review 5.  [Intra-operative local tumor cell dissemination in rectal carcinoma surgery: effect of operation principles and neoadjuvant therapy].

Authors:  S Merkel; W Hohenberger; P Hermanek
Journal:  Chirurg       Date:  2010-08       Impact factor: 0.955

Review 6.  Pelvic colorectal recurrence: crucial role of radiologists in oncologic and surgical treatment options.

Authors:  P A Georgiou; P P Tekkis; G Brown
Journal:  Cancer Imaging       Date:  2011-10-03       Impact factor: 3.909

7.  Expression of guanylyl cyclase C in tissue samples and the circulation of rectal cancer patients.

Authors:  Yong Liu; Guoping Cheng; Jun Qian; HaiXing Ju; YuPing Zhu; Meucci Stefano; Ulrich Keilholz; DeChuan Li
Journal:  Oncotarget       Date:  2017-06-13

8.  Pelvic exenteration: surgical approaches.

Authors:  Jin Kim
Journal:  J Korean Soc Coloproctol       Date:  2012-12-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.